Skip to main content
OpenTrials
Completed

NCT Number: NCT05989399

Evaluation of Circulating Neutrophils in Antisynthetase Syndrome

Antisynthetase syndrome (ASyS) is a rare and heteregeneous overlapping connective tissue disease, characterized by myositis, interstitial lung disease (ILD), joint involvement, Raynaud's phenomenon and cutaneous manifestations ("mechanic's hands"). Over 50% of patients develop ILD, which is the leading cause of death.

The role of neutrophils - innate immune cells involved in inflammatory processes and induced in particular by cytokines of the Th17 pathway - during AS is unknown. Direct pathogenic role of neutrophils has been described during idiopathic inflammatory myopathies, with an increase of netosis correlated with disease activity and muscle damage. During ASyS, a higher number of alveolar neutrophils has been observed in patients with rapidly progressive ILD.

There are few data on the specific evaluation of circulating neutrophils in ASyS. Investigators suppose that circulating neutrophils level could represent a simple and accessible severity biomarker in patients with ASyS.

The main objective is to evaluate the diagnostic performance of the circulating neutrophils level (> 7000/mm3) at diagnosis on ASyS severity.

The secondary objectives are:

* to define a threshold for circulating neutrophils levels at diagnosis allowing to predict ASyS severity and to assess the diagnostic performance of this threshold. * to define a threshold for the circulating neutrophils/lymphocytes ratio at diagnosis allowing to predict ASyS severity and to assess the diagnostic performance of this threshold. * to study the correlation between the level of circulating neutrophils and ASyS severity at diagnosis of the disease. * to study the correlation between the circulating neutrophils/lymphocytes ratio and ASyS severity at diagnosis of the disease. * to compare the circulating neutrophils level at ASyS diagnosis and after 1 year of treatment. * to compare the circulating neutrophils/lymphocytes ratio at ASyS diagnosis and after 1 year of treatment. * to compare patients characteristics according to ASyS severity at diagnosis. * to compare BAL fluid neutrophils level according to ILD severity at ASyS diagnosis in patients with ILD. * to compare BAL fluid neutrophils/lymphocytes ratio according to ILD severity at ASyS diagnosis in patients with ILD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Nancy

Nancy, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with ASyS diagnosis according to Connors criteria

Exclusion criteria

  • Active infection at ASyS diagnosis
  • Evolutive cancer at ASyS diagnosis
  • Corticosteroid therapy initiation before circulating neutrophils evaluation

Treatment and study plan

circulating neutrophils

Diagnostic Test

evaluation of circulating neutrophils level

Primary outcomes

  1. circulating neutrophils level > 7000/mm3

    Time frame: baseline (J0)

  2. number of patients with global severity

    Time frame: baseline (J0)

    global severity defined as presence of severe ILD (PaO2 < 600 mmHg or rapidly progressive ILD), and/or presence of severe myositis (bedrest, or MMT8 score < 30, or MRC muscle testing < 3/5, or swallowing disorers, or dysphagia) and/or presence of myocarditis on cardiac MRI

Secondary outcomes

  1. circulating neutrophils level

    Time frame: baseline (J0)

  2. circulating neutrophils/lymphocytes ratio

    Time frame: baseline (J0)

  3. FVC

    Time frame: baseline (J0)

    FVC percentage

  4. DLCO

    Time frame: baseline (J0)

    DLCO percentage

  5. grade of MRC muscle testing

    Time frame: baseline (J0)

  6. CK level

    Time frame: baseline (J0)

  7. circulating neutrophils level

    Time frame: 12 months

  8. circulating neutrophils/lymphocytes ratio

    Time frame: 12 months

  9. BAL fluid neutrophils level

    Time frame: baseline (J0)

  10. BAL fluid neutrophils/lymphocytes ratio

    Time frame: baseline (J0)

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Evaluation of Circulating Neutrophils in Antisynthetase Syndrome: a Multicenter Retrospective Study

Acronym: NEUTROSAS2

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 14, 2023
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.